医疗器械强劲销售“独木难支”，雅培Q1利润指引不及预期_老虎社区_美港股上老虎

医疗器械强劲销售“独木难支”，雅培Q1利润指引不及预期

智通财经网2025-01-22

1月22日，雅培周三公布的第一季度利润指引低于华尔街预期，同时第四季度除医疗器械以外的其他业务销售疲软，这导致其股价在盘前交易中下跌逾2%。数据显示，该公司Q4营收同比增长7.2%，达到109.7亿美元，但低于分析师平均预期的110.1亿美元。经调整后每股收益为1.34美元，符合分析师的平均预期。第四季度，该公司医疗器械部门的销售额达到50.52亿美元，同比增长13.7%，超出了分析师预期。由于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2505674744?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b","is_english":false,"pubTime":"2025-01-22 20:55","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2505674744","market":"us","top_or_hot":-1,"title":"医疗器械强劲销售“独木难支”，雅培Q1利润指引不及预期","media":"智通财经网","content":"<div>\n<p>1月22日，雅培周三公布的第一季度利润指引低于华尔街预期，同时第四季度除医疗器械以外的其他业务销售疲软，这导致其股价在盘前交易中下跌逾2%。数据显示，该公司Q4营收同比增长7.2%，达到109.7亿美元，但低于分析师平均预期的110.1亿美元。经调整后每股收益为1.34美元，符合分析师的平均预期。第四季度，该公司医疗器械部门的销售额达到50.52亿美元，同比增长13.7%，超出了分析师预期。由于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1242144.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医疗器械强劲销售“独木难支”，雅培Q1利润指引不及预期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医疗器械强劲销售“独木难支”，雅培Q1利润指引不及预期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-22 20:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1242144.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1月22日，雅培周三公布的第一季度利润指引低于华尔街预期，同时第四季度除医疗器械以外的其他业务销售疲软，这导致其股价在盘前交易中下跌逾2%。数据显示，该公司Q4营收同比增长7.2%，达到109.7亿美元，但低于分析师平均预期的110.1亿美元。经调整后每股收益为1.34美元，符合分析师的平均预期。第四季度，该公司医疗器械部门的销售额达到50.52亿美元，同比增长13.7%，超出了分析师预期。由于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1242144.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABT","symbol_name":"雅培","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1242144.html","article_id":"2505674744","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505674744","pubTimestamp":1737550538,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，雅培周三公布的第一季度利润指引低于华尔街预期，同时第四季度除医疗器械以外的其他业务销售疲软，这导致其股价在盘前交易中下跌逾2%。第四季度，该公司医疗器械部门的销售额达到50.52亿美元，同比增长13.7%，超出了分析师预期。雅培的的连续血糖监测器是2024年的关键增长动力，并且预计未来将继续推动其销售增长。但其营养、诊断和仿制药部门的销售额均低于预期。雅培表示，不包括与新冠检测相关的销售，营收增长了约10%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159883":"医疗器械","ABT":"雅培","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK1100":"医疗保健设备","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4585":"ETF&股票定投概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK1574":"生物医药B类股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK1583":"高瓴概念","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4566":"资本集团","SG9999002232.USD":"Allianz Global High Payout USD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","09996":"沛嘉医疗-B","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4082":"医疗保健设备","BK4592":"伊斯兰概念","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","BK4504":"桥水持仓","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","09997":"康基医疗","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4568":"美国抗疫概念","BK4588":"碎股","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK1222":"医疗保健用品","BK4581":"高盛持仓"},"translate_title":"Strong sales of medical devices are \"difficult to support alone\", Abbott's Q1 profit guidance falls short of expectations","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/2427d926cf5e1ffe9409bf93694ed2d4","symbols_score_info":{"159883":1,"09996":1,"09997":1,"ABT":1},"content_text":"1月22日，雅培周三公布的第一季度利润指引低于华尔街预期，同时第四季度除医疗器械以外的其他业务销售疲软，这导致其股价在盘前交易中下跌逾2%。数据显示，该公司Q4营收同比增长7.2%，达到109.7亿美元，但低于分析师平均预期的110.1亿美元。经调整后每股收益为1.34美元，符合分析师的平均预期。第四季度，该公司医疗器械部门的销售额达到50.52亿美元，同比增长13.7%，超出了分析师预期。由于人们对糖尿病护理意识的提高、保险覆盖范围的扩大以及对无需针刺的设备的偏好，雅培的FreeStyle Libre和德康医疗(DXCM.US)等竞争对手的连续血糖监测仪的销售都得到了提振。雅培的的连续血糖监测器是2024年的关键增长动力，并且预计未来将继续推动其销售增长。但其营养、诊断和仿制药部门的销售额均低于预期。雅培表示，不包括与新冠检测相关的销售，营收增长了约10%。展望未来，该公司预计，第一季度调整后每股收益为1.05至1.09美元，低于分析师平均预期的1.11美元。2025年调整后的每股收益为5.05至5.25美元，而分析师的平均预期为5.16美元。","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}